Esperion Therapeutics ESPR Quick ratio
Quick ratio at other companies
Other financials
Where this comes from
Calculated from Esperion Therapeutics’s reported figures.
Based on the most recent quarter.
The official record: Esperion Therapeutics’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Esperion Therapeutics's quick ratio.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Esperion Therapeutics's quick ratio?
- Esperion Therapeutics (ESPR) reported quick ratio of 1.2× in Q1 2026.
- How has Esperion Therapeutics's quick ratio changed year-over-year?
- Esperion Therapeutics's quick ratio increased by 46.0% year-over-year, from 0.8× to 1.2×.
- What is the long-term trend for Esperion Therapeutics's quick ratio?
- Over 5 years (2020 to 2025), Esperion Therapeutics's quick ratio has grown at a -19.5% compound annual growth rate (CAGR), from 3.5× to 1.2×.
- What does quick ratio mean?
- Current assets excluding inventory, divided by current liabilities at the quarter end (the 'acid-test'). A stricter liquidity measure that excludes the least-liquid current asset.